World Journal of Nuclear Medicine

REVIEW ARTICLE
Year
: 2021  |  Volume : 20  |  Issue : 4  |  Page : 329--335

Targeted alpha-particle therapy in neuroendocrine neoplasms: A systematic review


Thuan Tzen Koh1, Eva Bezak2, David Chan3, Gabrielle Cehic4 
1 Department of Nuclear Medicine and Radiology, Flinders Medical Center, Bedford Park, Australia
2 Centre for Translational Cancer Research, University of South Australia Cancer Research Institute, Adelaide, Australia
3 Department of Medical Oncology, Royal North Shore Hospital, Sydney, New South Wales, Australia
4 Department of Nuclear Medicine and Radiology, Flinders Medical Center, Bedford Park; Centre for Translational Cancer Research, University of South Australia Cancer Research Institute, Adelaide; Department of Nuclear Medicine, The Queen Elizabeth Hospital, Woodville, SA, Australia

Correspondence Address:
Dr. Thuan Tzen Koh
Department of Nuclear Medicine and Radiology, Flinders Medical Center, Level 2, Flinders Drive, Bedford Park, SA 5042
Australia

Neuroendocrine neoplasms (NENs) are a very diverse group of tumors with a worldwide rise in incidence. Systemic therapy remains the mainstay treatment for unresectable and/or metastatic NENs. 177Lu-DOTATATE, a radiopharmaceutical which emits beta particles, has emerged as a promising therapy for metastatic gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs). However, limited treatment options are available particularly after the failure of 177Lu-DOTATATE therapy. This review aims to identify and summarize the available evidence for, and potential adverse events of, targeted alpha-particle therapy (TAT) in the treatment of metastatic NENs, specifically GEP-NENs. The MEDLINE, EMBASE, SCOPUS, and Cochrane Library databases were searched. Two articles which met the inclusion criteria were identified and included in the review. Putative radiopharmaceuticals that can be considered for metastatic NEN treatment include 225Actinium (225Ac)-DOTATATE and 213Bismuth (213Bi)-DOTATOC. There was evidence of partial response using both radiopharmaceutical agents without significant hematological, renal, or hepatotoxicity. Future studies should consider longer term, randomized controlled trials investigating the role of TAT, in particular, 225Ac-DOTATATE, in the treatment of metastatic NENs.


How to cite this article:
Koh TT, Bezak E, Chan D, Cehic G. Targeted alpha-particle therapy in neuroendocrine neoplasms: A systematic review.World J Nucl Med 2021;20:329-335


How to cite this URL:
Koh TT, Bezak E, Chan D, Cehic G. Targeted alpha-particle therapy in neuroendocrine neoplasms: A systematic review. World J Nucl Med [serial online] 2021 [cited 2021 Nov 28 ];20:329-335
Available from: http://www.wjnm.org/article.asp?issn=1450-1147;year=2021;volume=20;issue=4;spage=329;epage=335;aulast=Koh;type=0